Jean-Claude Tardif, ESC 2018 – Results from the COMMANDER-HF Trial
Professor Jean-Claude Tardif (Montreal Heart Institute Research Centre and Professor of Medicine, University of Montreal, Montreal, Quebec, Canada) discusses the aims, rationale and recently released results of the COMMANDER-HF trial.
Filmed at ESC 2018, Munich.
View more content here.
Speaker Disclosure: Professor Jean-Claude Tardif has the following disclosures in relation to this video interview: grants from Amarin, AstraZeneca, DalCor, Esperion, Ionis, Pfizer, Sanofi and Servier. Honoraria from DalCor, Pfizer, Sanofi, Servier. Minor equity interest in DalCor.
1. Please describe the key aims of the COMMANDER-HF trial of rivaroxaban? (0:08)
2. What do we already know about the efficacy and safety of rivaroxaban and what was the rationale behind the COMMANDER-HF trial? (1:05)
3. Which patient groups were eligible for inclusion in the COMMANDER-HF trial? (2:28)
4. What separates the COMMANDER-HF trial from previous trials of oral anticoagulants in heart failure? (3:01)
5. What were the lessons from the COMMANDER-HF trial? (3:39)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via open-access content in multimedia formats.
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!